Global Vaccine Action Plan (GVAP) and Regional framework indicators

**Polio-free status sustained**
Yes
At least one dose of IPV introduced by end of 2015
Yes

**Country achieved MNT elimination**
Yes
Increasing trend in domestic expenditure since 2010
Yes

**Country verified for measles elimination**
Yes
NITAG established (with administrative/legal basis only)
Yes

**Seroprevalence of chronic hepatitis B infection (HBsAg) reduced to <1% in 5 year olds by 2017**
Yes
Functional NITAG (legal basis, TORs, ≥ 5 areas of expertise, ≥ 1 meeting per year, agenda and background docs, disclosure of conflict of interest)
Yes

**At least one new or underutilized vaccine introduced since 2010**
Yes
JE vaccine introduced in JE risk areas
Yes

**DTP3 national immunization coverage ≥95% by 2020**
98.1%
Primary series JE vaccine ≥ 90% coverage among children under 15 years old
97.3%

**DTP3 coverage ≥90% in at least 90% of districts (proportion of districts with ≥90% coverage)**
Yes (100%)
Case-based surveillance for invasive bacterial vaccine-preventable disease
No

**Sustained DTP3 coverage ≥95% for three or more years**
Yes
Case-based surveillance for rotavirus disease
No

**DTP dropout rate < 5%**
0.81%
Rubella and CRS case-based data submitted to WPRO
Rubella only

* New or underutilized vaccines include Hib, HPV, PCV and RV. IPV and JE are not counted. Otherwise, “Yes (specified)” is indicated to account for other vaccines.

---

**Population**

<table>
<thead>
<tr>
<th>Year</th>
<th>Drug dose</th>
<th>Total</th>
<th>Population</th>
<th>Source of data for NIP target</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>1 dose</td>
<td>51 529 338</td>
<td>50 293 439</td>
<td>JRF</td>
</tr>
<tr>
<td>2012</td>
<td>2 doses</td>
<td>435 969</td>
<td>457 036</td>
<td>Registered population</td>
</tr>
<tr>
<td>2013</td>
<td>≥ 3 doses</td>
<td>433 930</td>
<td>455 237</td>
<td>UN*</td>
</tr>
</tbody>
</table>

* United Nations World Population Prospects: The 2015 Revision

---

**Financial Resources**

<table>
<thead>
<tr>
<th>Year</th>
<th>Gross national income per capita (US $)</th>
<th>Line item in budget for vaccines</th>
<th>% of vaccines in routine immunization funded by government</th>
<th>% of routine immunization - funded by government</th>
<th>Eligible for GAVI support</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>$27 440</td>
<td>Yes</td>
<td>100%</td>
<td>100%</td>
<td>No</td>
</tr>
</tbody>
</table>

---

**Reported cases of selected vaccine preventable diseases**

<table>
<thead>
<tr>
<th>Year</th>
<th>Acute flaccid paralysis (AFP)</th>
<th>Measles</th>
<th>Rubella</th>
<th>Congenital rubella syndrome (CRS)</th>
<th>Neonatal tetanus</th>
<th>Total tetanus</th>
<th>Diphtheria</th>
<th>Pertussis</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>Non-polio AFP rate % adequate specimens</td>
<td>Cases IR</td>
<td>Cases IR</td>
<td>Cases IR</td>
<td>Cases IR</td>
<td>Cases IR</td>
<td>Cases IR</td>
<td>Cases IR</td>
</tr>
<tr>
<td>2012</td>
<td>0.4  69%</td>
<td>42 0.9</td>
<td>53 1.1</td>
<td>0 0.0</td>
<td>19 0.0</td>
<td>0 0.0</td>
<td>97 0.2</td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td>1.1  93%</td>
<td>17 2.2</td>
<td>107 2.2</td>
<td>1 0.0</td>
<td>0 0.0</td>
<td>0 0.0</td>
<td>36 0.1</td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td>1.2  86%</td>
<td>11 0.2</td>
<td>442 8.9</td>
<td>0 0.0</td>
<td>0 0.0</td>
<td>26 0.1</td>
<td>76 0.2</td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td>1.2  86%</td>
<td>7 0.1</td>
<td>43 0.9</td>
<td>0 0.0</td>
<td>22 0.0</td>
<td>0 0.0</td>
<td>205 0.4</td>
<td></td>
</tr>
</tbody>
</table>

---

**Confirmed measles cases by month of onset 2011-2015**

**Confirmed measles cases by age group and vaccination status, 2014-2015**

---

**Invasive bacterial disease, rotavirus and Japanese encephalitis**

<table>
<thead>
<tr>
<th>Year</th>
<th>Surveillance diarrhea</th>
<th>Japanese encephalitis</th>
<th>Bacterial meningitis</th>
<th>Bacterial pneumonia</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>Sentinel (106 sites)</td>
<td>1430</td>
<td>Nationwide</td>
<td>14</td>
</tr>
<tr>
<td>2014</td>
<td>Sentinel (68 sites)</td>
<td>709</td>
<td>Nationwide</td>
<td>26</td>
</tr>
<tr>
<td>2015</td>
<td>Sentinel (70 sites)</td>
<td>588</td>
<td>Nationwide</td>
<td>40</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Year</th>
<th>Surveillance system type</th>
<th>Confirmed cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>Nationwide</td>
<td>Pneumo - 9 Meningo - 4</td>
</tr>
</tbody>
</table>

---

Non-polio AFP rate = incidence per 100 000 under 15 years; % adequate specimen = % of AFP cases with 2 specimens within 14 days of paralysis onset.

IR = incidence rate: for measles and rubella, per 1 000 000 population; for CRS and neonatal tetanus, per 1000 live births; for all others, per 100 000 population. Total tetanus includes neonatal tetanus cases.

Republic of Korea, 2015

Immunization schedule

<table>
<thead>
<tr>
<th>BCG</th>
<th>M-M1</th>
<th>DTP</th>
<th>M2, M4, M6, M15-18, Y4-6</th>
<th>HepA</th>
<th>M12-23, +M6-12</th>
<th>JE liveatd</th>
<th>M12-23, M24-35</th>
</tr>
</thead>
<tbody>
<tr>
<td>Td</td>
<td>Y11-12</td>
<td>DTP-IPV</td>
<td>M2, M4, M6, Y4-6</td>
<td>HepB</td>
<td>B, M1, M6</td>
<td>JE inactd</td>
<td>M12-23, +D7-30, +M12, Y6, Y12</td>
</tr>
<tr>
<td>TdaP</td>
<td>Y11-12</td>
<td>IPV</td>
<td>M2, M4, M6, Y4-6</td>
<td>Hib</td>
<td>M2, M4, M6</td>
<td>HFRS</td>
<td>1st contact, +M1, +Y1</td>
</tr>
<tr>
<td>Varicella</td>
<td>M12-15</td>
<td>Pneumo conj</td>
<td>M2, M4, M6, M12-15</td>
<td>MMR</td>
<td>M12-15, Y4-6</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NIP priority needs

1. Introduction of new vaccines into the National Immunization Program according to the priority
2. To control and eliminate vaccine-preventable diseases through maintaining high vaccination coverage
3. Safe vaccination

Immunization schedule

BCG = birth, W = week, M = month, Y = year

Planning

- Multi-year plan (MYP): Yes
- Annual workplan for immunization activities: Yes
- Updated wild poliovirus importation and cVDPV response plan: Yes

Safe immunization

- % districts using auto-disable syringes: 100%
- System to monitor AEFI: Yes
- Number of AEFI: 271
- Injection safety policy implemented: Yes
- Disposal methods: Incineration, Other
- Injection safety review: Yes (National)

Delivery of immunization services

- % of population served by outreach
- No. (%) of districts with DTP3 coverage < 80%: 0 (0%)
- No. (%) of districts with DTP3 coverage ≥ 90%: 255 (100%)
- No. (%) of districts with MCV1 coverage < 80%: 0 (0%)
- No. (%) of districts with MCV1 coverage ≥ 90%: 255 (100%)
- No. (%) of districts with DTP drop-out > 10%: 0 (0%)
- No. (%) of districts with DTP1—MCV1 drop-out > 10%: 0 (0%)

Safe immunization

% districts using auto-disable syringes: 100%
System to monitor AEFI: Yes
Number of AEFI: 271
Injection safety policy implemented: Yes
Disposal methods: Incineration, Other
Injection safety review: Yes (National)

Number of children in districts, by category of DTP3 coverage, 2014–2015

- Number of children: 425,682
- Category of DTP3 coverage: 433,930

Reports of immunization coverage, 2006–2015

- Immunization coverage (%): 2014
- Immunization coverage (%): 2015

Surveys

- Most recent (year): 2014
- Type: Computer-assisted Telephone Interview with random sampling (CATI)
- Geographical representativeness: National
- Result: 94.7%

School-based immunization

- Is there a school entry requirement?: Yes
- If no, do schools check immunization status at enrolment?:
- What vaccines are required/checked?: Pre-school - BCG, HepB, DTaP, IPV, Hib, PCV, MMR, Varicella, JEV
Primary - DTaP, Polio, MMR, JEV
- At what school level/year?:
- Is routine vaccination given at school?: No
- Which vaccination?:
- If yes, is this part of a comprehensive school-health program that delivers other health interventions?:

Measles and rubella elimination

- Confirmed measles case rate* (per 1 million population): 0.1
- Year of MCV1 introduction: 1983
- Confirmed rubella case rate* (per 1 million population): 0.0
- Year of MCV2 introduction: 1997
- Discarded as non-measles rate* (Target: ≥ 2 per 100 000 population): 0.6
- Year of RCV introduction: 1983
- % suspected cases with adequate specimens* (Target: ≥ 80%): 74.9%
- Surveillance conducted for CRS: Yes (Nationwide)
- Imported measles cases* : 3
- Antigens, year and target population of last SIA: MR - 2001 (8-16 yrs)
- Measles cases with unknown source of infection*: 3
- Number vaccinated (SIA coverage): 5,614,327 (96%)

Hepatitis B Control

- Year HepB3 vaccine introduced nationwide: 1983
- Year HepB birth dose introduced: 1983
- HepB birth dose (within 24 hours) coverage: 93%
- HepB birth dose (within and after 24 hours) coverage: 98.9%
- Systems to deliver HepB vaccine birth dose: Hospitals, health centers
- HBsAg results assessed for blood donors: Yes
- Policy for screening of pregnant women: Yes
- Policy to vaccinate health care workers: Yes

* Data from measles monthly country reports to WHO